alexa On the Potential Use of Genetically Modified Mesenchymal Stem Cells to Treat Articular Cartilage Defects | OMICS International
ISSN: 2161-0533
Orthopedic & Muscular System: Current Research

Like us on:

Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

On the Potential Use of Genetically Modified Mesenchymal Stem Cells to Treat Articular Cartilage Defects

Magali Cucchiarini*

Saarland University Medical Center, Homburg/Saar, Germany

*Corresponding Author:
Magali Cucchiarini, Ph.D
Associate Professor in Molecular Biology
Center of Experimental Orthopaedics
Saarland University Medical Center
Kirrbergerstr. Homburg/Saar, Germany
Tel: ++49-6841-1624987
Fax: ++49-6841-1624988
E-mail: [email protected]

Received Date: September 17, 2012; Accepted Date: September 26, 2012; Published Date: October 01, 2012

Citation: Cucchiarini M (2012) On the Potential Use of Genetically Modified Mesenchymal Stem Cells to Treat Articular Cartilage Defects. Orthop Muscul Syst 1: e106. doi: 10.4172/2161-0533.1000e106

Copyright: © 2012 Cucchiarini M. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Orthopedic & Muscular System: Current Research

Damage to articular cartilage, the tissue that allows for a smooth gliding of the articulating surface of a joint (and to withstand high loads), is an unsolved problem, especially following joint trauma [1]. As adult, hyaline cartilage is aneural, avascular, and without a lymphatic drainage, it does not have access to reparative cells that may be brought locally in response toinjury. Defects (partial or full-thickness) of the cartilage thus do not heal on themselves and instead, tend to become persistent and progress inevitably, often towards osteoarthritis [2].

Current options for cartilage repair are diverse (marrowstimulating techniques, transplantation of tissue or cells, replacement surgery), yet none can reliably regenerate thenatural functions of the cartilage, including its integrity (type-II and not type-I collagen), the adherence of the repair tissue to the surrounding cartilage, and the ability of withstanding mechanical stress over time.

Considerable efforts have been made to improve the repair processes and in particular, the promise of treating cartilage defects by cell- and gene-based approaches has attracted much attention [3-7]. Indeed, administration of candidate genes, rather than recombinant factors with short half-lives, might be a means to promote sustained repair like for disorders showing a gradual progression. The development of strategies using the implantation of genetically modified mesenchymal stem cells (MSCs) as therapeutic platforms might prove beneficial to enhance cartilage repair during surgical procedures. As a matter of fact, MSCs might be better suited for this purpose than committed cells such as chondrocytes that require more invasive methods of extraction and tend to lose their phenotype upon culture. Also, MSCs have the ability to recapitulate lineage transitions originally involved in mesenchymal tissue formation (cartilage, bone, fat tissue), among which a potential for chondrogenesis [8-10]. MSCs further display critical tropic activities and demonstrate, interestingly, a broad panel of immunomodulatory properties. MSCs can be isolated from the bone marrow, bone, adipose tissue, muscle, synovium, periosteum, and perichondrium. It is important to note that genetic modification of such cells might also allow to overcome some of the limitations stillassociated with their use, like the large amount of cells needed for application in vivo, the relatively low percentage of which enter proper chondrogenic pathways to produce a functional, reparative tissue, and the decline of lifespan and potency seen in pathological conditions (in OA patients, for instance) [11,12]. For cartilage repair, a challenge will be also to maintain the cells in a prehypertrophic state that avoids premature terminal differentiation, hypertrophy, and ossification [10,13-15].

Genetic manipulation of MSCs to enhance their potency for chondrogenesis and cartilage repair has been attempted using different gene delivery vectors, including nonviral systems as well as adenoviral, retro-/lentiviral, and recombinant adeno-associated viral (rAAV) vectors, without altering their multilineage potential [16-25]. Beneficial effects upon MSC chondrogenic differentiation in vitro have been reported by transfer of gene sequences coding for growth (TGF-β, BMPs, IGF-I, FGF-2) and transcription factors (SOX5, SOX6, SOX9,ZNF145), or signaling molecules (hedgehogs, PTHrP) [6,26,27]. Most remarkably, several experimental studies have evidenced the feasibility of applying genetically modified MSCs (commonly as cell suspensions, three-dimensional cultures, coagulates, in conjunction with biomaterials, or even as tissue grafts) to successfully improve the repair of cartilage defects in vivo using many of the gene candidates cited above [19,21,28-36]. It remains to be seen now whether this approach will meet decisive success in patients, as no known clinical trial is ongoing for the treatment of articular cartilage defects by administration of gene-modified MSCs.


Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Recommended Conferences

Article Usage

  • Total views: 11715
  • [From(publication date):
    December-2012 - Jul 18, 2018]
  • Breakdown by view type
  • HTML page views : 7938
  • PDF downloads : 3777

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

+1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals


[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
Leave Your Message 24x7